Acute Myeloid Leukemia

Acute Myeloid Leukemia

Time-Dependent Treatment Effects of Metronomic Chemotherapy in Unfit AML Patients

This study examines the presence of the time-dependent effect of metronomic chemotherapy for the treatment of older patients with AML who were unfit for standard chemotherapy...

The Metabolic Reprogramming in Acute Myeloid Leukemia Patients Depends on Their Genotype and is a Prognostic Marker

Leukemic cells display some alterations in metabolic pathways, which play a role in leukemogenesis and in patients’ prognosis.

Blood Advances
Outcomes of Pediatric Acute Myeloid Leukemia Patients With FLT3-ITD Mutations in the Pre-FLT3 Inhibitor Era

This study aims to analyze the outcomes of pediatric AML patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era.


Enriching for Human Acute Myeloid Leukemia Stem Cells Using Reactive Oxygen Species-Based Cell Sorting

Isolation of leukemia stem cells presents a challenge due to the heterogeneity of the immunophenotypic markers commonly used to identify blood stem cells.

Clinical Features and Outcomes of Hypocellular Acute Myeloid Leukemia in Adults

Study investigators perform a retrospective analysis of the clinical features and survival outcomes of hypocellular AML in a Korean population.

Differentiation Therapy of Myeloid Leukemia

AML is characterized by arrested differentiation, and agents that overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic acid in...

A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia

Study investigators develop a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML.

SIRPαFc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Hematologic and solid tumors can upregulate expression of CD47, a self-marker that binds to SIRPα, an immunoglobulin superfamily receptor expressed on...

Acute Macular Neuroretinopathy in a Patient With Acute Myeloid Leukemia and Deceased by COVID-19

This study aims to report a case of acute macular neuroretinopathy and underlying disease of acute myeloid leukemia.

Azelaic Acid Exerts Antileukemia Effects against Acute Myeloid Leukemia by Regulating the Prdxs/ROS Signaling Pathway

The findings indicate that AZA may be a potential agent against AML by regulating the Prdxs/ROS signaling pathway.

LT-171-861, a Novel FLT3 Inhibitor, Shows Excellent Preclinical Efficacy for the Treatment of FLT3 Mutant Acute Myeloid Leukemia

Given that aberrant activation of FLT3 acts as a critical survival signal for cancer cells in 20‒30% patients with AML, inhibition of FLT3 may be a potential therapeutic strategy.

Maintenance Therapy in Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Relapse remains the main cause of treatment failure in acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Measurable Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphological Relapse in the Majority of Patients with Core-Binding Factor Acute Myeloid Leukemia

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11.

Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia

Little is known about the roles of M-MDSCs in acute myeloid leukemia as opposed to their multiple roles in solid tumors.

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia blasts.

Frontiers in Oncology
Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients With NPM1-Mutated AML

Measurable residual disease monitoring is of prognostic relevance in NPM1mut acute myeloid leukemia patients.

Long Non-Coding RNA ZNF667-AS1 Knockdown Curbs Liver Metastasis in Acute Myeloid Leukemia by Regulating the microRNA-206/AKAP13 Axis

This study's goal is to probe the functional mechanism of ZNF667-AS1 in AML by mediating microRNA-206 (miR-206)/A-kinase anchoring protein 13 (AKAP13) axis.

Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia

ZEB1 expression was downregulated in AML patients, and Zeb1 KO in the malignant counterparts of HSCs—leukemic stem cells— accelerated MLL-AF9– and Meis1a/Hoxa9-d

Journal of Clinical Investigation
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

Both CBF-AML entities are characterized by chromosomal rearrangements involving the CBF transcriptional complex, leading to abnormal fusion proteins that block myeloid differentiation.

Blood Advances
IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells

Study results suggest a potential clinical utility of IGFBP7 and ATRA combination treatment to eliminate primary AML cells and reduce relapse in AML patients.

Blood Advances
Chimeric Antigen Receptor-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia

This study discusses the current status of CAR-modified IEC therapies for AML, with considerations regarding suitable, relatively leukemia-restricted target antigens, expected toxicities...

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

The following study reviews the current knowledge on AML LSC identification and targeting via surface antigens with a focus on heterogeneity among different AML subgroups and genetic backgrounds.

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

Insight into Leukemia stem cells and assessment of cell surface markers have enabled characterization of LSCs from hematopoietic stem and progenitor cells.

Frontiers in Oncology
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

AML is the most common form of acute leukemia in adults and second most common form of acute leukemia in children. Despite this, very little improvement in survival rates...

Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?

This study presents cases of three patients with AML with varying cytogenetic and molecular risks to demonstrate the important but changing role of patient fitness in the current...

Management of toxicities associated with targeted therapies for Acute Myeloid Leukemia: When to Push Through and When to Stop

The goal of this review is to help clinicians determine the risk:benefit ratio in decision making for individual patients with AML.

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature

This study aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in leukemic stem cells.

Natural killer cell-based immunotherapy for acute myeloid leukemia

This review summarized different forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials.

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia

This study reviewed the latest insights in AML biology concerning refractoriness to therapies with a specific focus on cytarabine and daunorubicin which still represent milestones agents for...

International Journal of Molecular Sciences
TP-0903 is active in models of drug-resistant acute myeloid leukemia

Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance.

Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway

The bone marrow microenvironment in acute myeloid leukemia consists of various cell types that support the growth of AML cells and protect them from chemotherapy. 

Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects

This comprehensive review highlights and discusses recent advances in ML techniques in the management of AML as a model disease of hematologic neoplasms...

Blood Advances
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia

This review discussed FLT3 as a target and highlight current understanding of FLT3 inhibitor resistance.

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myeloid leukemia remains a challenge despite the development of novel FLT3-directed...

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

This study investigated the combination effects of radotinib and Ara-C on AML.

BMC Cancer
New directions for emerging therapies in acute myeloid leukemia: the next chapter

Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, followed by consolidation therapy, including...

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

This study summarizes the current knowledge about the preemptive and prophylactic use of pharmacologic agents after allo-HSCT to prevent relapse of AML.

Frontiers in Oncology
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development

Recently, numerous advancements have been made within the realm of AML therapy, including genetically targeted therapies against FLT3, IDH1/2 and tumor protein p53, antibody-drug conjugate

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

This study characterized a new multiple kinase inhibitor, ARQ531, and evaluate its mechanism of action in preclinical models of acute myeloid leukemia.

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

The SITC convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of ALL and AML.

A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia

Recently age-specific differences in AML have been identified, highlighting the need for tailored treatments for paediatric patients.

Scientific Reports
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

Notably, venetoclax-based combinations have improved outcomes, including both remission rates and overall survival, of older patients with AML deemed “unfit” for intensive...

Frontiers in Oncology
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

Overexpression of BCL-2 proteins in acute myeloid leukemia can circumvent resistance to apoptosis and chemotherapy.

Frontiers in Oncology
Immune prognostic risk score model in acute myeloid leukemia with normal karyotype

NK-AML is a group of diseases with high heterogeneity and immunological processes are significantly associated with its initiation and development.

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives

The increasing knowledge of AML in the elderly is currently being associated with a multidimensional approach to identify eligibility and design tailored transplant platforms.

Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy

Like normal hematopoietic stem cells, leukemic stem cells depend on their bone marrow microenvironment for survival, but the underlying mechanisms remain largely unknown.


source list reference